Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Mirex seems to promote a unique group of skin cells different from those affected by another tumor promoter, TPA.

Lower SMAD2/3 activation predicts more severe skin cancer.

Baricitinib works better than methotrexate for severe alopecia areata.

Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

Ruxolitinib helped a patient with alopecia areata regrow hair.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.

Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.

Tofacitinib helped regrow hair in a lupus patient with alopecia.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Rapamycin may help treat Leigh syndrome by targeting protein kinase C.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

M50054 may help treat hepatitis and hair loss from chemotherapy.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

Targeted anticancer therapies in children often cause skin side effects like rash and dry skin.

JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

JAK inhibitors show promise in treating difficult skin diseases.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.

The protein p21 is more abundant in normal skin cells than in melanoma cells and may help protect against melanoma, with UVB light affecting its levels.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

NBCCS and BFHS might be the same syndrome, helping better identify and manage cases.